Longeveron(US:LGVN) Globenewswire·2025-09-03 20:05Leadership Changes - Longeveron Inc. appointed Than Powell as interim Chief Executive Officer, succeeding Wa'el Hashad who left to pursue other opportunities [1][6] - Dr. Joshua Hare, the founder and Chief Science Officer, has been appointed as Executive Chairman of the Board [1][6] - The Board plans to conduct a national search for a permanent CEO [1][6] Pipeline and Clinical Trials - Longeveron has a robust pipeline centered on laromestrocel, a stem cell therapy, with positive initial outcomes in five clinical trials across three indications [2] - The pivotal Phase 2b clinical trial for laromestrocel as a treatment for hypoplastic left heart syndrome (HLHS) has achieved full enrollment, with top-line results expected in 2026 [2] - The company has expanded its pipeline to include pediatric dilated cardiomyopathy, advancing three unique programs to pivotal clinical trial stage [2][7] Regulatory Designations - Laromestrocel has received five important FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the HLHS program, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the Alzheimer's disease program [7]